pyrazinecarboxamide - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	pyrazinecarboxamide	go back to main search page
Accession:	CHEBI:45285	browse the term
Definition:	A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.
Synonyms:	related_synonym:	2-carbamylpyrazine; 2-pyrazinecarboxamide; Formula=C5H5N3O; InChI=1S/C5H5N3O/c6-5(9)4-3-7-1-2-8-4/h1-3H,(H2,6,9); InChIKey=IPEHBUMCGVEMRF-UHFFFAOYSA-N; PYRAZINE-2-CARBOXAMIDE; Pyrazinoic acid amide; SMILES=NC(=O)c1cnccn1; pyrazinamida; pyrazinamide; pyrazinamidum; pyrazine carboxamide; pyrazineamide
	alt_id:	CHEBI:45281; CHEBI:8656
	xref:	Beilstein:112306; CAS:98-96-4; DrugBank:DB00339; Drug_Central:2328; Gmelin:279021; HMDB:HMDB0014483; KEGG:C01956; KEGG:D00144; LINCS:LSM-5425
	xref_mesh:	MESH:D011718
	xref:	PDBeChem:PZA; PMID:14977529; PMID:18517115; PMID:18604033; Reaxys:112306; Wikipedia:Pyrazinamide

show annotations for term's descendants Sort by:
Rat (119) Mouse (111) Human (111) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (119)

pyrazinecarboxamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

increases expression

Pyrazinamide results in increased expression of ABCA1 mRNA

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily A member 3

decreases expression

Pyrazinamide results in decreased expression of ABCA3 mRNA

NCBI chr10:13,382,439...13,439,748
Ensembl chr10:13,382,540...13,439,745

G

ATP binding cassette subfamily B member 11

decreases expression
multiple interactions

Pyrazinamide results in decreased expression of ABCB11 mRNA; Pyrazinamide results in decreased expression of ABCB11 protein
obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of ABCB11 mRNA]
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCB11 protein

PMID:27255380 PMID:35835356

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 4

multiple interactions
decreases expression

obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of ABCB4 mRNA]
Pyrazinamide results in decreased expression of ABCB4 mRNA; Pyrazinamide results in decreased expression of ABCB4 protein

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily B member 6

increases expression

Pyrazinamide results in increased expression of ABCB6 mRNA

NCBI chr 9:76,668,554...76,677,263
Ensembl chr 9:76,668,554...76,676,924

G

ATP binding cassette subfamily C member 2

multiple interactions
decreases expression

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCC2 protein; obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of ABCC2 mRNA]
Pyrazinamide results in decreased expression of ABCC2 mRNA; Pyrazinamide results in decreased expression of ABCC2 protein

PMID:27255380 PMID:35835356

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

increases expression

Pyrazinamide results in increased expression of ABCC3 mRNA; Pyrazinamide results in increased expression of ABCC3 protein

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP-binding cassette, subfamily G (WHITE), member 3-like 1

decreases expression

Pyrazinamide results in decreased expression of ABCG3L1 mRNA

NCBI chr14:5,124,541...5,177,265
Ensembl chr14:5,124,353...5,177,184

G

acetyl-CoA acyltransferase 1A

increases expression
multiple interactions

Pyrazinamide results in increased expression of ACAA1 mRNA
Fenofibrate promotes the reaction [Pyrazinamide results in increased expression of ACAA1 mRNA]; Pyrazinamide promotes the reaction [Fenofibrate results in increased expression of ACAA1 mRNA]

PMID:22431067 PMID:27071702

NCBI chr 8:119,079,401...119,088,626
Ensembl chr 8:119,079,775...119,088,624

G

acetyl-Coenzyme A acyltransferase 1B

increases expression

Pyrazinamide results in increased expression of ACAA1B mRNA

NCBI chr 8:118,872,996...118,881,852
Ensembl chr 8:118,872,997...118,881,825

G

acyl-CoA synthetase long-chain family member 4

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of ACSL4 protein

NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427

G

acyl-CoA synthetase medium-chain family member 2

increases expression

Pyrazinamide results in increased expression of ACSM2 mRNA

NCBI chr 1:173,916,368...173,955,116
Ensembl chr 1:173,916,368...173,955,116

G

aldo-keto reductase family 7 member A3

increases expression

Pyrazinamide results in increased expression of AKR7A3 mRNA

NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394

G

aldehyde dehydrogenase 1 family, member A1

increases expression

Pyrazinamide results in increased expression of ALDH1A1 mRNA

NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961

G

aldehyde dehydrogenase 1 family, member L1

increases expression

Pyrazinamide results in increased expression of ALDH1L1 mRNA

NCBI chr 4:123,059,989...123,106,471
Ensembl chr 4:123,060,008...123,106,465

G

alkB homolog 2, alpha-ketoglutarate-dependent dioxygenase

decreases expression

Pyrazinamide results in decreased expression of ALKBH2 mRNA

NCBI chr12:42,494,187...42,500,929
Ensembl chr12:42,496,300...42,500,914

G

apolipoprotein A1

multiple interactions
increases expression

[Fenofibrate co-treated with Pyrazinamide] results in increased expression of APOA1 mRNA
Pyrazinamide results in increased expression of APOA1 mRNA

PMID:22431067 PMID:27071702

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

asparagine synthetase (glutamine-hydrolyzing)

increases expression

Pyrazinamide results in increased expression of ASNS mRNA

NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423

G

activating transcription factor 3

increases expression

Pyrazinamide results in increased expression of ATF3 mRNA

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

activating transcription factor 4

multiple interactions
increases expression

4-phenylbutyric acid inhibits the reaction [Pyrazinamide results in increased expression of ATF4 protein]
Pyrazinamide results in increased expression of ATF4 mRNA; Pyrazinamide results in increased expression of ATF4 protein

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

activating transcription factor 6

increases expression

Pyrazinamide results in increased expression of ATF6 mRNA

NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177

G

Bcl2-like 10

decreases expression

Pyrazinamide results in decreased expression of BCL2L10 mRNA

NCBI chr 8:76,107,326...76,113,373
Ensembl chr 8:76,107,326...76,113,367

G

Bcl2-like 2

decreases expression

Pyrazinamide results in decreased expression of BCL2L2 mRNA

NCBI chr15:28,346,449...28,361,627
Ensembl chr15:28,356,807...28,361,624

G

BAF chromatin remodeling complex subunit BCL7C

increases expression

Pyrazinamide results in increased expression of BCL7C mRNA

NCBI chr 1:182,277,163...182,324,274
Ensembl chr 1:182,260,164...182,324,163

G

Bcl2 modifying factor

decreases expression

Pyrazinamide results in decreased expression of BMF mRNA

NCBI chr 3:105,499,534...105,520,159
Ensembl chr 3:105,499,538...105,520,145

G

caspase 3

increases cleavage
multiple interactions

Pyrazinamide results in increased cleavage of CASP3 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CASP3

PMID:28063906 PMID:35835356

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

decreases expression
multiple interactions

Pyrazinamide results in decreased expression of CAT protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CAT protein

PMID:28425350 PMID:36878459

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cell division cycle and apoptosis regulator 1

decreases expression

Pyrazinamide results in decreased expression of CCAR1 mRNA

NCBI chr20:30,685,916...30,728,531
Ensembl chr20:30,685,916...30,728,526

G

cyclin E2

decreases expression

Pyrazinamide results in decreased expression of CCNE2 mRNA

NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632

G

cyclin-dependent kinase 20

decreases expression

Pyrazinamide results in decreased expression of CDK20 mRNA

NCBI chr17:701,122...707,869
Ensembl chr17:701,124...707,826

G

cyclin-dependent kinase 4

increases expression

Pyrazinamide results in increased expression of CDK4 mRNA

NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403

G

cyclin dependent kinase inhibitor 2D

increases expression

Pyrazinamide results in increased expression of CDKN2D mRNA

NCBI chr 8:19,831,874...19,834,640
Ensembl chr 8:19,831,866...19,834,674

G

CCAAT/enhancer binding protein beta

increases expression

Pyrazinamide results in increased expression of CEBPB mRNA

NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473

G

CCAAT/enhancer binding protein delta

increases expression

Pyrazinamide results in increased expression of CEBPD mRNA

NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829

G

collagen type I alpha 1 chain

increases expression

Pyrazinamide results in increased expression of COL1A1 mRNA

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

carnitine palmitoyltransferase 1B

decreases expression
multiple interactions

Pyrazinamide results in decreased expression of CPT1B mRNA
Fenofibrate inhibits the reaction [Pyrazinamide results in decreased expression of CPT1B mRNA]

PMID:22431067 PMID:27071702

NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases expression

Pyrazinamide results in increased expression of CYP1A2 mRNA

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 2, subfamily b, polypeptide 1

increases expression

Pyrazinamide results in increased expression of CYP2B1 mRNA

NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052

G

cytochrome P450, family 2, subfamily b, polypeptide 2

increases expression

Pyrazinamide results in increased expression of CYP2B2 mRNA

NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566

G

cytochrome P450, family 2, subfamily b, polypeptide 21

increases expression

Pyrazinamide results in increased expression of CYP2B21 mRNA

NCBI chr 1:81,886,097...81,915,066
Ensembl chr 1:81,886,098...81,915,066

G

cytochrome P450, family 2, subfamily d, polypeptide 4

increases expression

Pyrazinamide results in increased expression of CYP2D4 mRNA

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 2, subfamily d, polypeptide 5

increases expression

Pyrazinamide results in increased expression of CYP2D5 mRNA

NCBI chr 7:113,899,905...113,904,458
Ensembl chr 7:113,899,890...113,904,495

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 2, subfamily j, polypeptide 3

decreases expression

Pyrazinamide results in decreased expression of CYP2J3 mRNA

NCBI chr 5:111,219,921...111,244,987
Ensembl chr 5:111,178,703...111,244,794

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

increases expression

Pyrazinamide results in increased expression of CYP3A23-3A1 mRNA

NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030

G

cytochrome P450, family 3, subfamily a, polypeptide 9

decreases expression

Pyrazinamide results in decreased expression of CYP3A9 mRNA

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

cytochrome P450, family 51

increases expression

Pyrazinamide results in increased expression of CYP51 mRNA

NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
Ensembl chr 6:30,036,865...30,055,410

G

cytochrome P450 family 7 subfamily A member 1

increases expression
multiple interactions

Pyrazinamide results in increased expression of CYP7A1 mRNA; Pyrazinamide results in increased expression of CYP7A1 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CYP7A1 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CYP7A1 protein

PMID:27255380 PMID:35835356

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

cytochrome P450 family 8 subfamily B member 1

decreases expression
increases expression

Pyrazinamide results in decreased expression of CYP8B1 mRNA; Pyrazinamide results in decreased expression of CYP8B1 protein
Pyrazinamide results in increased expression of CYP8B1 mRNA

PMID:22431067 PMID:27255380

NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166

G

DNA-damage inducible transcript 3

multiple interactions
increases expression

4-phenylbutyric acid inhibits the reaction [Pyrazinamide results in increased expression of DDIT3 protein]
Pyrazinamide results in increased expression of DDIT3 mRNA; Pyrazinamide results in increased expression of DDIT3 protein

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

dual specificity tyrosine phosphorylation regulated kinase 2

decreases expression

Pyrazinamide results in decreased expression of DYRK2 mRNA

NCBI chr 7:54,348,724...54,381,363
Ensembl chr 7:54,349,610...54,380,106

G

eukaryotic translation initiation factor 2 alpha kinase 3

multiple interactions
increases phosphorylation

4-phenylbutyric acid inhibits the reaction [Pyrazinamide results in increased phosphorylation of EIF2AK3 protein]

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

eukaryotic translation initiation factor 2 subunit alpha

increases phosphorylation
multiple interactions

Pyrazinamide results in increased phosphorylation of EIF2S1 protein
4-phenylbutyric acid inhibits the reaction [Pyrazinamide results in increased phosphorylation of EIF2S1 protein]

NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225

G

E1A binding protein p300

decreases expression

Pyrazinamide results in decreased expression of EP300 mRNA

NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088
Ensembl chr 7:113,106,247...113,136,088

G

epoxide hydrolase 1

increases expression

Pyrazinamide results in increased expression of EPHX1 mRNA

NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235

G

ERCC excision repair 1, endonuclease non-catalytic subunit

increases expression

Pyrazinamide results in increased expression of ERCC1 mRNA

NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963

G

endoplasmic reticulum to nucleus signaling 1

increases expression

Pyrazinamide results in increased expression of ERN1 mRNA

NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029

G

fatty acid binding protein 1

multiple interactions
decreases expression

Fenofibrate inhibits the reaction [Pyrazinamide results in decreased expression of FABP1 mRNA]

NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788

G

fatty acid binding protein 7

decreases expression

Pyrazinamide results in decreased expression of FABP7 mRNA

NCBI chr20:37,123,193...37,126,725
Ensembl chr20:37,123,193...37,126,880

G

F-box and WD repeat domain containing 11

decreases expression

Pyrazinamide results in decreased expression of FBXW11 mRNA

NCBI chr10:17,232,735...17,330,574
Ensembl chr10:17,227,181...17,330,571

G

flavin containing dimethylaniline monoxygenase 1

increases expression

Pyrazinamide results in increased expression of FMO1 mRNA

NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647

G

growth arrest and DNA-damage-inducible, alpha

increases expression

Pyrazinamide results in increased expression of GADD45A mRNA

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

growth arrest-specific 2

increases expression

Pyrazinamide results in increased expression of GAS2 mRNA

NCBI chr 1:101,452,361...101,582,619
Ensembl chr 1:101,482,591...101,582,619

G

glutamic--pyruvic transaminase

increases expression
multiple interactions
increases activity

Pyrazinamide results in increased expression of GPT protein
4-phenylbutyric acid inhibits the reaction [Pyrazinamide results in increased expression of GPT protein]; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPT protein; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein; Fenofibrate inhibits the reaction [Pyrazinamide results in increased expression of GPT protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]
Pyrazinamide results in increased activity of GPT protein

PMID:27071702 PMID:28063906 PMID:28425350 PMID:35835356 PMID:36878459

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 4

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]

NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982

G

glutathione S-transferase alpha 4

increases expression

Pyrazinamide results in increased expression of GSTA4 mRNA

NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182

G

glutathione S-transferase alpha 5

increases expression

Pyrazinamide results in increased expression of GSTA5 mRNA

NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472

G

glutathione S-transferase mu 1

increases expression

Pyrazinamide results in increased expression of GSTM1 mRNA

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

glutathione S-transferase mu 2

increases expression

Pyrazinamide results in increased expression of GSTM2 mRNA

NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961

G

glutathione S-transferase pi 1

increases expression

Pyrazinamide results in increased expression of GSTP1 mRNA

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

glutathione S-transferase theta 1

multiple interactions

GSTT1 gene polymorphism results in increased susceptibility to [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide]

NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

3-hydroxy-3-methylglutaryl-CoA synthase 1

increases expression

Pyrazinamide results in increased expression of HMGCS1 mRNA

NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100

G

3-hydroxy-3-methylglutaryl-CoA synthase 2

increases expression

Pyrazinamide results in increased expression of HMGCS2 mRNA

NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130

G

heme oxygenase 1

increases expression

Pyrazinamide results in increased expression of HMOX1 mRNA

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

hydroxysteroid 11-beta dehydrogenase 1

increases expression

Pyrazinamide results in increased expression of HSD11B1 mRNA

NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687

G

heat shock protein family A (Hsp70) member 5

multiple interactions
increases expression

4-phenylbutyric acid inhibits the reaction [Pyrazinamide results in increased expression of HSPA5 protein]
Pyrazinamide results in increased expression of HSPA5 mRNA; Pyrazinamide results in increased expression of HSPA5 protein

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

inositol 1,4,5-trisphosphate receptor, type 1

decreases expression

Pyrazinamide results in decreased expression of ITPR1 mRNA

NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491

G

lipoprotein lipase

decreases expression
multiple interactions

Pyrazinamide results in decreased expression of LPL mRNA
Fenofibrate inhibits the reaction [Pyrazinamide results in decreased expression of LPL mRNA]

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

malic enzyme 1

increases expression

Pyrazinamide results in increased expression of ME1 mRNA

PMID:22431067 PMID:27071702

NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304

G

microsomal glutathione S-transferase 3

increases expression

Pyrazinamide results in increased expression of MGST3 mRNA

NCBI chr13:79,526,541...79,547,479
Ensembl chr13:79,526,541...79,547,411

G

Mix paired-like homeobox 1

decreases expression

Pyrazinamide results in decreased expression of MIXL1 mRNA

NCBI chr13:92,422,031...92,426,065
Ensembl chr13:92,422,031...92,426,065

G

mitochondrial ribosomal protein S14

decreases expression

Pyrazinamide results in decreased expression of MRPS14 mRNA

NCBI chr13:72,429,168...72,434,915
Ensembl chr13:72,408,558...72,434,915

G

nuclear receptor subfamily 0, group B, member 2

multiple interactions
decreases expression

obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of NR0B2 mRNA]

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions
decreases expression

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of NR1H4; obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of NR1H4 mRNA]
Pyrazinamide results in decreased expression of NR1H4 mRNA; Pyrazinamide results in decreased expression of NR1H4 protein

PMID:27255380 PMID:35835356

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

NAD(P) dependent steroid dehydrogenase-like

increases expression

Pyrazinamide results in increased expression of NSDHL mRNA

NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142

G

neurotrophic receptor tyrosine kinase 1

decreases expression

Pyrazinamide results in decreased expression of NTRK1 mRNA

NCBI chr 2:173,236,961...173,253,806
Ensembl chr 2:173,236,963...173,253,770

G

p53 apoptosis effector related to PMP22

increases expression

Pyrazinamide results in increased expression of PERP mRNA

NCBI chr 1:13,542,067...13,554,514
Ensembl chr 1:13,542,067...13,554,511

G

phosphoglycerate dehydrogenase

increases expression

Pyrazinamide results in increased expression of PHGDH mRNA

NCBI chr 2:185,906,962...185,936,054
Ensembl chr 2:185,906,966...185,935,944

G

peroxisome proliferator activated receptor alpha

multiple interactions
decreases expression

[Pyrazinamide co-treated with Glucose] binds to PPARA protein; Pyrazinamide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]
Pyrazinamide results in decreased expression of PPARA mRNA; Pyrazinamide results in decreased expression of PPARA protein
Fenofibrate inhibits the reaction [Pyrazinamide results in decreased expression of PPARA mRNA]

PMID:18812576 PMID:27071702

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

protein phosphatase 2 scaffold subunit A alpha

increases expression

Pyrazinamide results in increased expression of PPP2R1A mRNA

NCBI chr 1:60,540,223...60,559,467
Ensembl chr 1:60,540,194...60,560,129

G

prominin 1

decreases expression

Pyrazinamide results in decreased expression of PROM1 mRNA

NCBI chr14:66,989,545...67,094,534
Ensembl chr14:66,990,160...67,094,527

G

solute carrier family 10 member 1

increases expression
multiple interactions

Pyrazinamide results in increased expression of SLC10A1 mRNA; Pyrazinamide results in increased expression of SLC10A1 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of SLC10A1

PMID:27255380 PMID:35835356

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

solute carrier family 16, member 11

decreases expression

Pyrazinamide results in decreased expression of SLC16A11 mRNA

NCBI chr10:54,929,129...54,933,021
Ensembl chr10:54,927,725...54,942,915

G

solute carrier family 17 member 1

increases expression

Pyrazinamide results in increased expression of SLC17A1 mRNA

NCBI chr17:41,219,461...41,255,199
Ensembl chr17:41,222,049...41,253,304

G

solute carrier family 22 member 12

affects activity

Pyrazinamide affects the activity of SLC22A12 protein

NCBI chr 1:203,845,039...203,852,496
Ensembl chr 1:203,845,048...203,853,555

G

solute carrier family 22 member 13

decreases expression

Pyrazinamide results in decreased expression of SLC22A13 mRNA

NCBI chr 8:118,922,367...118,934,020
Ensembl chr 8:118,922,367...118,953,635

G

solute carrier family 25, member 39

increases expression

Pyrazinamide results in increased expression of SLC25A39 mRNA

NCBI chr10:87,362,494...87,367,358
Ensembl chr10:87,362,490...87,367,260

G

solute carrier family 25 member 4

decreases expression

Pyrazinamide results in decreased expression of SLC25A4 mRNA

NCBI chr16:46,072,935...46,076,730
Ensembl chr16:46,072,939...46,076,733

G

solute carrier family 25, member 42

decreases expression

Pyrazinamide results in decreased expression of SLC25A42 mRNA

NCBI chr16:19,213,914...19,251,990
Ensembl chr16:19,213,950...19,237,025

G

solute carrier family 29 member 1

decreases expression

Pyrazinamide results in decreased expression of SLC29A1 mRNA

NCBI chr 9:15,399,661...15,414,203
Ensembl chr 9:15,399,612...15,414,203

G

solute carrier family 51 member A

decreases expression

Pyrazinamide results in decreased expression of SLC51A mRNA; Pyrazinamide results in decreased expression of SLC51A protein

NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485

G

SLC51 subunit beta

multiple interactions
decreases expression

obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of SLC51B mRNA]
Pyrazinamide results in decreased expression of SLC51B mRNA; Pyrazinamide results in decreased expression of SLC51B protein

NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145

G

solute carrier family 6 member 9

decreases expression

Pyrazinamide results in decreased expression of SLC6A9 mRNA

NCBI chr 5:131,374,562...131,408,733
Ensembl chr 5:131,374,542...131,408,728

G

solute carrier family 7 member 10

decreases expression

Pyrazinamide results in decreased expression of SLC7A10 mRNA

NCBI chr 1:87,829,084...87,845,073
Ensembl chr 1:87,829,175...87,845,071

G

solute carrier family 7 member 11

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]

NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536

G

solute carrier organic anion transporter family, member 1a4

increases expression

Pyrazinamide results in increased expression of SLCO1A4 mRNA; Pyrazinamide results in increased expression of SLCO1A4 protein

NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573

G

solute carrier organic anion transporter family member 1B2

decreases expression
multiple interactions

Pyrazinamide results in decreased expression of SLCO1B2 mRNA; Pyrazinamide results in decreased expression of SLCO1B2 protein
obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of SLCO1B2 mRNA]

NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981

G

solute carrier organic anion transporter family, member 4a1

decreases expression

Pyrazinamide results in decreased expression of SLCO4A1 mRNA

NCBI chr 3:167,559,177...167,578,307
Ensembl chr 3:167,559,316...167,578,305

G

spermidine synthase

increases expression

Pyrazinamide results in increased expression of SRM mRNA

NCBI chr 5:159,025,875...159,029,076
Ensembl chr 5:159,025,873...159,029,405

G

sulfotransferase family 1C member 2A

decreases expression

Pyrazinamide results in decreased expression of SULT1C2A mRNA

NCBI chr 9:6,873,697...6,904,736
Ensembl chr 9:6,874,249...6,904,734

G

sulfotransferase family 2A member 1

decreases expression

Pyrazinamide results in decreased expression of SULT2A1 mRNA

NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134

G

TOPBP1-interacting checkpoint and replication regulator

decreases expression

Pyrazinamide results in decreased expression of TICRR mRNA

NCBI chr 1:133,597,618...133,639,513
Ensembl chr 1:133,597,716...133,639,523

G

transmembrane protein 176A

increases expression

Pyrazinamide results in increased expression of TMEM176A mRNA

NCBI chr 4:77,774,940...77,778,620
Ensembl chr 4:77,774,843...77,778,620

G

UDP glucuronosyltransferase 1 family, polypeptide A2

increases expression

Pyrazinamide results in increased expression of UGT1A2 mRNA

NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

voltage-dependent anion channel 1

increases expression

Pyrazinamide results in increased expression of VDAC1 mRNA

NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640

G

X-box binding protein 1

increases expression

Pyrazinamide results in increased expression of XBP1 mRNA alternative form

NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta

increases expression

Pyrazinamide results in increased expression of YWHAH mRNA

NCBI chr14:77,696,332...77,705,715
Ensembl chr14:77,696,333...77,705,741

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19874
role	19844
application	19689
pro-agent	11549
prodrug	11293
pyrazinecarboxamide	119
N-butyl-5-(4-hydroxyphenyl)-6-oxo-1,6-dihydropyrazine-2-carboxamide	0
Path 2
Term	Annotations
CHEBI ontology	19874
subatomic particle	19872
composite particle	19872
hadron	19872
baryon	19872
nucleon	19872
atomic nucleus	19872
atom	19872
main group element atom	19811
p-block element atom	19811
carbon group element atom	19751
carbon atom	19748
organic molecular entity	19748
heteroorganic entity	19505
organochalcogen compound	19268
organooxygen compound	19184
carbon oxoacid	18654
carboxylic acid	18651
carboacyl group	17694
univalent carboacyl group	17694
carbamoyl group	17545
carboxamide	17545
monocarboxylic acid amide	15727
pyrazinecarboxamide	119
N-butyl-5-(4-hydroxyphenyl)-6-oxo-1,6-dihydropyrazine-2-carboxamide	0

paths to the root